Literature DB >> 12853883

Protection against oxaliplatin acute neurosensory toxicity by venlafaxine.

Jean-Philippe Durand1, Catherine Brezault, François Goldwasser.   

Abstract

Venlafaxine (Effexor; Wyeth Lederlé) has previously shown therapeutic effects for the management of chronic and neuropathic pains. We report here the efficacy of venlafaxine upon acute neurosensory symptoms secondary to oxaliplatin toxicity. A dose of 50 mg of venlafaxine was given orally at the beginning of the oxaliplatin infusion. Patients did not experience any or very low paresthesias, even in the cold. As the results were very dramatic and reproducible, we propose that venlafaxine may be of use in the daily management of oxaliplatin-related neurosensory toxicity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853883     DOI: 10.1097/00001813-200307000-00006

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  18 in total

Review 1.  Therapeutic strategies for cancer treatment related peripheral neuropathies.

Authors:  Deirdre R Pachman; James C Watson; Charles L Loprinzi
Journal:  Curr Treat Options Oncol       Date:  2014-12

2.  Repeated administration of mirtazapine attenuates oxaliplatin-induced mechanical allodynia and spinal NR2B up-regulation in rats.

Authors:  Xiaoyu Liu; Guangfen Zhang; Lin Dong; Xingming Wang; Heliang Sun; Jinchun Shen; Weiyan Li; Jianguo Xu
Journal:  Neurochem Res       Date:  2013-07-09       Impact factor: 3.996

3.  Chemotherapy-induced neuropathy.

Authors:  Guido Cavaletti; Paola Alberti; Barbara Frigeni; Marialuisa Piatti; Emanuela Susani
Journal:  Curr Treat Options Neurol       Date:  2011-04       Impact factor: 3.598

4.  Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study.

Authors:  Stefan von Delius; Florian Eckel; Stefan Wagenpfeil; Martina Mayr; Konrad Stock; Frank Kullmann; Florian Obermeier; Johannes Erdmann; Renate Schmelz; Stefan Quasthoff; Helmuth Adelsberger; Rainer Bredenkamp; Roland M Schmid; Christian Lersch
Journal:  Invest New Drugs       Date:  2006-09-13       Impact factor: 3.850

Review 5.  Interventions for preventing neuropathy caused by cisplatin and related compounds.

Authors:  James W Albers; Vinay Chaudhry; Guido Cavaletti; Ross C Donehower
Journal:  Cochrane Database Syst Rev       Date:  2011-02-16

Review 6.  [Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options].

Authors:  T Kowalski; C Maier; A Reinacher-Schick; U Schlegel
Journal:  Schmerz       Date:  2008-02       Impact factor: 1.107

7.  MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy.

Authors:  Collin Zimmerman; Pamela J Atherton; Deirdre Pachman; Drew Seisler; Nina Wagner-Johnston; Shaker Dakhil; Jacqueline M Lafky; Rui Qin; Axel Grothey; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2015-08-08       Impact factor: 3.603

8.  Oxaliplatin-induced neuropathy in colorectal cancer.

Authors:  Andrew Weickhardt; Keith Wells; Wells Messersmith
Journal:  J Oncol       Date:  2011-12-12       Impact factor: 4.375

9.  Defeating cancer with antidepressants.

Authors:  J Lieb
Journal:  Ecancermedicalscience       Date:  2008-08-21

10.  Chemotherapy-induced peripheral neuropathy. Part II. Prevention.

Authors:  Krzysztof Brzeziński
Journal:  Contemp Oncol (Pozn)       Date:  2012-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.